Monopar Therapeutics, which is developing therapies for chemotherapy-induced mucositis and cancers, raised $9 million by offering 1.1 million shares at $8, the low end of the range of $8 to $10, to command an $89 million market value. Insiders indicated on $6 million worth of shares in the offering (67%).
Monopar Therapeutics plans to list on the Nasdaq under the symbol MNPR. JonesTrading and Arcadia Securities acted as lead managers on the deal.
